Prevalence and clinicopathologic features of mismatch repair–deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Universal tumor testing is increasingly recommended for Lynch syndrome (LS). However, data involving younger Japanese patients are still limited. This study aimed to prospectively evaluate the prevalence and clinicopathologic profile of DNA mismatch repair (MMR)–deficient (dMMR) endometrial cancers (EC) in patients aged under 50 years, and characterize immunohistochemical (IHC) loss patterns and genetic testing results. Methods Consecutive patients with EC aged under 50 years were prospectively enrolled at a single Japanese institution. Diagnostic specimens underwent MMR IHC ( MLH1, MSH2, MSH6 , and PMS2 ). Clinicopathologic variables were compared between proficient MMR (pMMR) and dMMR. Results Among 85 patients, 20 (23.5%) had dMMR. Grades differed when dichotomized as G1 versus G2–G3 ( p < 0.01). FIGO stage distribution also varied between groups ( p = 0.021); stage I was 53/65 (81.5%) in pMMR and 11/20 (55.0%) in dMMR ( p = 0.035). Among dMMR tumors, IHC patterns were loss of MLH1/PMS2 ( n = 10), loss of MSH2/MSH6 ( n = 5), and isolated loss of MSH6 ( n = 5). Of the 8 (40.0%) patients with dMMR who underwent germline testing, 5 had LS ( MLH1/PMS2 loss: 1/3; MSH2/MSH6 loss: 3/3; MSH6 isolated loss: 1/2). The overall dMMR prevalence in this young cohort was comparable to that in all-age series from multiple regions. Conclusions In this prospective Japanese cohort, approximately one in four patients with EC had dMMR, with clinicopathologic features skewing toward a higher grade. Notably, many dMMR tumors were grade 2–3, thereby not eligible for fertility-sparing treatment.
